Table 1. Patients’ characteristics at baseline.
| Characteristics | All N=450 |
LABC N=306 |
IBC N=144 |
P-value |
|---|---|---|---|---|
| Median age at diagnosis (years, range) | 49 (19-85) | 49 (19-78) | 50.5 (27-85) | 0.791 |
| Menopause | 0.835 | |||
| no | 238 (55%) | 163 (56%) | 75 (54%) | |
| yes | 192 (45%) | 129 (44%) | 63 (46%) | |
| Clinical axillary lymph node status, cN | 6.87E-03 | |||
| 0 | 98 (22%) | 56 (18%) | 42 (30%) | |
| 1-3 | 347 (78%) | 249 (82%) | 98 (70%) | |
| Pathological type | 0.939 | |||
| ductal | 372 (83%) | 254 (83%) | 118 (83%) | |
| lobular | 39 (9%) | 26 (8%) | 13 (9%) | |
| other | 37 (8%) | 26 (8%) | 11 (8%) | |
| Pathological grade | 4.67E-02 | |||
| 1 | 33 (8%) | 23 (8%) | 10 (7%) | |
| 2 | 167 (39%) | 125 (43%) | 42 (31%) | |
| 3 | 231 (54%) | 146 (50%) | 85 (62%) | |
| Molecular subtype, IHC status | 0.632 | |||
| HR + | 208 (46%) | 145 (47%) | 63 (44%) | |
| HER2 + | 144 (32%) | 98 (32%) | 46 (32%) | |
| TN | 98 (22%) | 63 (21%) | 35 (24%) | |
| Dermal emboli | 1.43E-16 | |||
| no | 248 (79%) | 183 (94%) | 65 (54%) | |
| yes | 67 (21%) | 12 (6%) | 55 (46%) | |
| Neoadjuvant chemotherapy | 1.05E-12 | |||
| anthracycline | 94 (21%) | 34 (11%) | 60 (42%) | |
| anthracycline & taxane | 356 (79%) | 272 (89%) | 84 (58%) | |
| Surgery | 1.16E-14 | |||
| mastectomy | 340 (76%) | 202 (66%) | 138 (97%) | |
| lumpectomy | 108 (24%) | 103 (34%) | 5 (3%) | |
| Adjuvant radiotherapy | 1 | |||
| no | 13 (3%) | 9 (3%) | 4 (3%) | |
| yes | 431 (97%) | 295 (97%) | 136 (97%) | |
| Neoadjuvant/adjuvant trastuzumab | 3.63E-03 | |||
| no | 335 (74%) | 215 (70%) | 120 (83%) | |
| yes | 115 (26%) | 91 (30%) | 24 (17%) | |
| Adjuvant hormone therapy | 0.117 | |||
| no | 173 (40%) | 109 (37%) | 64 (45%) | |
| yes | 261 (60%) | 184 (63%) | 77 (55%) |